Judge rules against the sale of Gilenya generics amidst Novartis’ patent trial 27-Jun-2019 By Maggie Lynch US Federal court judge rules for Novartis to keep exclusivity of blockbuster MS drug until patent issues are settled.
UPDATED Teva dealt double Copaxone blow amid sales slowdown 15-Oct-2018 By Ben Hargreaves Teva's appeal to protect Copaxone's patents fell through and competitor product, Gilenya, received strong comparative data in the same week.
Novartis launches legal offensive to protect Gilenya patents 23-Jul-2018 By Ben Hargreaves Novartis has begun legal action against a number of drugmakers to block any generic versions of Gilenya coming to market.